Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30206% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Product Revenues — Diagnostic Testing Services by Quarter
Product Revenues — Diagnostic Testing Services ($M) ($M)
Natera Product Revenues — Diagnostic Testing Services: $748M in Q2 2026, up 37.4% from a year earlier. That is the highest of the 37 quarters on record here.
Latest, Q2 2026
748
Period ended Jun 30, 2026
Change on a year earlier
+37.4%
544 in Q2 2025
History
37 quarters
Since Q2 2017
Sources
28
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (2026-08-07) ↗
Reported in Form 10-K/10-Q (DB).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Product Revenues — Diagnostic Testing Services ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 748 | +37.4% | Form 10-Q (2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 694 | +38.8% | Form 10-Q (2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 661 | +39.8% | Form 10-K (2026-02-27) ↗ |
| Q3 2025 | Sep 30, 2025 | 590 | +35.3% | Form 10-Q (2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 544 | +32.3% | Form 10-Q (2025-08-08) ↗ |
| Q1 2025 | Mar 31, 2025 | 500 | +37.1% | Form 10-Q (2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 473 | +53.9% | Form 10-K (2025-02-28) ↗ |
| Q3 2024 | Sep 30, 2024 | 436 | +64.4% | Form 10-Q (2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 411 | +59.3% | Form 10-Q (2024-08-09) ↗ |
| Q1 2024 | Mar 31, 2024 | 365 | +53.4% | Form 10-Q (2024-05-10) ↗ |
| Q4 2023 | Dec 31, 2023 | 307 | +44.3% | Form 10-K (2024-02-29) ↗ |
| Q3 2023 | Sep 30, 2023 | 265 | +32.7% | Form 10-Q (2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 258 | +32.7% | Form 10-Q (2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 238 | +25.2% | Form 10-Q (2023-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 213 | +28.2% | Form 10-K (2023-03-01) ↗ |
| Q3 2022 | Sep 30, 2022 | 200 | +29.8% | Form 10-Q (2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 195 | +39.4% | Form 10-Q (2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 190 | +57.8% | Form 10-Q (2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 166 | +41.8% | Form 10-K (2023-03-01) ↗ |
| Q3 2021 | Sep 30, 2021 | 154 | +65.0% | Form 10-Q (2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 140 | +73.6% | Form 10-Q (2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 120 | +38.4% | Form 10-Q (2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 117 | +57.2% | Form 10-K (2023-03-01) ↗ |
| Q3 2020 | Sep 30, 2020 | 93.3 | +39.5% | Form 10-Q (2020-11-06) ↗ |
| Q2 2020 | Jun 30, 2020 | 80.4 | +23.5% | Form 10-Q (2020-08-07) ↗ |
| Q1 2020 | Mar 31, 2020 | 87 | +37.2% | Form 10-Q (2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 74.5 | +18.1% | Form 10-K (2020-03-02) ↗ |
| Q3 2019 | Sep 30, 2019 | 66.9 | +6.7% | Form 10-Q (2019-11-08) ↗ |
| Q2 2019 | Jun 30, 2019 | 65.1 | +7.8% | Form 10-Q (2019-08-09) ↗ |
| Q1 2019 | Mar 31, 2019 | 63.4 | +16.8% | Form 10-Q (2019-05-10) ↗ |
| Q4 2018 | Dec 31, 2018 | 63.1 | +26.5% | Form 10-K (2019-03-15) ↗ |
| Q3 2018 | Sep 30, 2018 | 62.7 | +15.0% | Form 10-Q (2018-11-09) ↗ |
| Q2 2018 | Jun 30, 2018 | 60.4 | +18.7% | Form 10-Q (2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 54.3 | – | Form 10-Q (2019-05-10) ↗ |
| Q4 2017 | Dec 31, 2017 | 49.9 | – | Form 10-K (2019-03-15) ↗ |
| Q3 2017 | Sep 30, 2017 | 54.5 | – | Form 10-Q (2018-11-09) ↗ |
| Q2 2017 | Jun 30, 2017 | 50.9 | – | Form 10-Q (2018-08-09) ↗ |
Cite this data
StockData. (2026). Natera Product Revenues — Diagnostic Testing Services ($M), quarterly Q2 2017–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/db-seg-product-rev
See every metric in the Natera KPI table. Data updated Nov 2, 2026.